STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Human cell"
DOI: 10.1007/s13577-021-00582-4
Abstract: Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to… read more here.
Keywords: hcc827 cells; inhibitor; gefitinib; stat3 inhibitor ... See more keywords
The Stat3 inhibitor, S3I-201, downregulates lymphocyte activation markers, chemokine receptors, and inflammatory cytokines in the BTBR T+ Itpr3tf/J mouse model of autism
Sign Up to like & getrecommendations! Published in 2019 at "Brain Research Bulletin"
DOI: 10.1016/j.brainresbull.2019.07.006
Abstract: Autism is a complex neurodevelopmental disorder with a high incidence rate. It is characterized by deficits in communication, a lack of social skills, cognitive inflexibility, and stereotypical behaviors. Autism has been gradually increasing in children… read more here.
Keywords: autism; stat3 inhibitor; btbr mice; btbr itpr3tf ... See more keywords
Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells
Sign Up to like & getrecommendations! Published in 2019 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2018.1539496
Abstract: Abstract In the present study, solid lipid nanoparticles (SLNs) have been formulated as a carrier system for effective intracellular delivery of STAT3 inhibitor, niclosamide (Niclo) to triple negative breast cancer (TNBC) cells. Emulsification-solvent evaporation method… read more here.
Keywords: negative breast; niclo slns; stat3 inhibitor; solid lipid ... See more keywords
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22179105
Abstract: Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by the progressive obstruction of the distal pulmonary arteries (PA). Structural and functional alteration of pulmonary artery smooth muscle cells (PASMC) and endothelial cells (PAEC)… read more here.
Keywords: expression; bmpr2 expression; bmpr2; stat3 inhibitor ... See more keywords
Novel Activity of ODZ10117, a STAT3 Inhibitor, for Regulation of NLRP3 Inflammasome Activation
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24076079
Abstract: The NLRP3 inflammasome serves as a host defense mechanism against various pathogens, but there is growing evidence linking its activation in sterile condition to diverse inflammatory diseases. Therefore, the identification of specific inhibitors that target… read more here.
Keywords: activity; inflammasome activation; activation; nlrp3 inflammasome ... See more keywords
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2023.12968
Abstract: Signal transducer and activator of transcription 3 (STAT3) signalling serves an important role in carcinogenesis and cellular senescence, and its inhibition in tumour cells represents an attractive therapeutic target. Premature cellular senescence, a process of… read more here.
Keywords: stattic analogues; tumour cells; stat3; senescence ... See more keywords
Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.63125
Abstract: Repeated cycles of first-line chemotherapy drugs such as doxorubicin (DOX) and cisplatin (CIS) trigger frequent chemoresistance in recurrent urothelial bladder cancer (UBC). Nitroxoline (NTX), an antibiotic to treat urinary tract infections, has been recently repurposed… read more here.
Keywords: cis; drug resistant; t24 dox; stat3 inhibitor ... See more keywords